OncoMatch/Clinical Trials/NCT06947083
Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma
Is NCT06947083 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Elranatamab for myeloma.
Treatment: Elranatamab — The purpose of the study is to evaluate the effect of Elranatamab therapy after cilta-cel measuring how long a patient with high risk relapsed myeloma lives without the myeloma getting worse(progressing), also known as progression-free survival (PFS). Patients with clinical high-risk myeloma, defined as having history of myeloma that has grown outside of the bones or having high risk mutations in the myeloma cells, benefit less from cilta-cel compared to myeloma patients without these characteristics.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Biomarker criteria
Required: TP53 del17p
high risk cytogenetics by IMW (del17p, or t(4;14) or t(14;16) or history of EMD)
Required: IGH t(4;14)
high risk cytogenetics by IMW (del17p, or t(4;14) or t(14;16) or history of EMD)
Required: IGH t(14;16)
high risk cytogenetics by IMW (del17p, or t(4;14) or t(14;16) or history of EMD)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: CAR-T cell therapy (cilta-cel) — commercial
Have received commercial cilta-cel within 3-6 months for relapsed refractory myeloma
Must have received: immunomodulatory drug
Have received >2 prior treatment regimens including an immunomodulatory drug
Must have received: proteasome inhibitor
Have received >2 prior treatment regimens including ... a proteasome inhibitor
Must have received: CD38 monoclonal antibody
Have received >2 prior treatment regimens including ... a CD38 monoclonal antibody
Lab requirements
Blood counts
Must have adequate bone marrow function
Kidney function
Patients with renal failure requiring dialysis [excluded]; renal insufficiency secondary to multiple myeloma permitted
Liver function
Serum bilirubin levels ≤1.5 times the upper limit of the normal range for the laboratory (ULN), unless related to Gilbert syndrome; Serum AST or serum ALT levels ≤2 x ULN
Serum bilirubin levels ≤1.5 times ULN, unless related to Gilbert syndrome; Serum AST or ALT ≤2 x ULN; Must have adequate bone marrow function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Moffitt Cancer Center · Tampa, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify